The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice

Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases

(2012) Sung-Jun Park et al.   CELL

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease

(2011) Klaus F. Rabe   BRITISH JOURNAL OF PHARMACOLOGY

Therapy in the Early Stage: Incretins

(2011) S. Cernea et al.   DIABETES CARE

Emerging GLP-1 receptor agonists

(2011) Asger Lund et al.   EXPERT OPINION ON EMERGING DRUGS

Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide

(2011) G. Lahu et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model

(2010) Gezim Lahu et al.   CLINICAL PHARMACOKINETICS

The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease

(2010) Armin Hatzelmann et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release

(2009) WK Ong et al.   BRITISH JOURNAL OF PHARMACOLOGY

Regulation of AMP-activated protein kinase by cAMP in adipocytes: Roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis

(2009) Bilal Omar et al.   CELLULAR SIGNALLING

Low- and High-Density Lipoproteins Modulate Function, Apoptosis, and Proliferation of Primary Human and Murine Pancreatic β-Cells

(2009) Sabine Rütti et al.   ENDOCRINOLOGY

Reduced Adiposity and High-Fat Diet-Induced Adipose Inflammation in Mice Deficient for Phosphodiesterase 4B

(2009) Ren Zhang et al.   ENDOCRINOLOGY

Segmentation of the Pathophysiological Stages of Diabetic Changes in the db/db Mouse

(2009) Masaki Yamazaki et al.   Journal of Toxicologic Pathology

Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets

(2008) Deena Waddleton et al.   BIOCHEMICAL PHARMACOLOGY

RD Lawrence Lecture 2008 Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes

(2008) F. M. Gribble   DIABETIC MEDICINE